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Abstract In this report we have studied the role of phosphati-
dylinositol 3P-kinase (PI3-K) and tyrosine phosphatase activation
on platelet activation by Convulxin (Cvx). Wortmannin, a
specific PI3-K inhibitor, and phenylarsine oxide (PAO), a
sulfhydryl reagent that inhibits tyrosine phosphatase (PTPase),
block Cvx-induced platelet aggregation, granule secretion,
inositol phosphate production, and increase in [Ca2+]i. However,
PAO does not inhibit Cvx-induced tyrosine phosphorylation of
platelet proteins, including Syk and PLCQ2, but blocked
collagen-induced platelet aggregation as well as tyrosine
phosphorylation of PLCQ2. In contrast, Cvx-induced PLCQ2
tyrosyl phosphorylation was partially inhibited by wortmannin.
We conclude that (i) although Cvx and collagen activate platelets
by a similar mechanism, different regulatory processes are
specific to each agonist; (ii) mechanisms other than tyrosine
phosphorylation regulate PLCQ2 activity; and (iii) besides
protein tyrosine kinases, PI3-K (and PTPase) positively
modulate platelet activation by both Cvx and collagen, and this
enzyme is required for effective transmission of GPVI-Fc
receptor Q chain signal to result in full activation and tyrosine
phosphorylation of PLCQ2 in Cvx-stimulated platelets.
z 1999 Federation of European Biochemical Societies.
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1. Introduction
Convulxin is a 72 kDa glycoprotein, isolated from the ven-
om of Crotalus durissus terri¢cus and Crotalus durissus casca-
vella, composed of 3K (13.9 kDa) and 3L (12.6 kDa) chains
linked by disul¢de bridges performing an K3L3 heterodimeric
complex [1,2]. The cloning of both subunits of Cvx has re-
cently been reported [3], and they present sequence homology
with the carbohydrate recognition domain of the C-type lectin
family; however, Cvx does not function as a lectin, as it does
not induce agglutination of erythrocytes in a number of spe-
cies [4]. Cvx is a potent inducer of platelet activation [5] and
binds with high a⁄nity to rabbit [4] and human [6] platelets.
Cvx activates PLC [7] by a mechanism that is not blocked by
the cyclooxygenase inhibitor aspirin, by the PAF antagonist
WEB 2086, and/or by the ADP scavenger enzymatic system
CP/CPK, indicating that PLC activation is independent of the
secondary agonist produced by activated platelets [5,7]. Cvx-
induced PLC activation is, however, blocked by inhibitors
acting on the protein tyrosine kinases, genistein and stauro-
sporine [8]. Actually, Cvx stimulates a rapid tyrosine phos-
phorylation of several platelet proteins, including PLCQ2, by
a mechanism independent of ¢brinogen interaction with integ-
rin KIIbL3 and insensitive to cAMP [8,9]. This early event is
followed by the dephosphorylation of several proteins in a
platelet aggregation-dependent manner [8,9]. It has been
shown that Cvx binds to the putative collagen receptor
GPVI [6,10] and that Cvx-mediated platelet adhesion, platelet
aggregation, and [Ca2]i mobilization are blocked by the Fab
fragments of a polyclonal anti-GPVI antibody [6]. More re-
cently, it has also been shown that GPVI physically associates
with the Fc receptor Q chain [11,12] and that this complex
associates physically and functionally with the Src family kin-
ases Fyn and Lyn [13]. A model has been proposed to explain
the early steps of signaling by both Cvx [9] and collagen [14].
Accordingly, GPVI ligation by both molecules induces Src
kinase activation, leading to tyrosyl phosphorylation of the
ITAM motif of the Fc receptor Q chain and subsequent tyrosyl
phosphorylation of Syk and PLCQ2 [8^17]. This model clearly
shows that a cascade of kinase activation is essential for
PLCQ2 tyrosyl phosphorylation by collagen and Cvx; how-
ever, PLC activation is modulated in a number of cells by
additional mechanisms, e.g. the identi¢cation of the tyrosine
phosphatases (PTPases) CD45 and SHP1 as positive and neg-
ative regulators, respectively, of lymphocyte signaling [17].
More recently, the identi¢cation of PI3-K, a lipid kinase, as
another enzyme involved in the regulation of phosphoinosi-
tide metabolism and PLCQ activation upon stimulation by
growth factor receptors, indicates that phosphoinositide me-
tabolism is under the control of di¡erent enzymes [18,19]. In
fact, phosphorylation of phosphatidylinositol 4,5-bisphos-
phate (PIP2) by phosphatidylinositol 3P-kinase (PI3-K) leads
to the production of phosphatidylinositol 3,4,5-trisphosphate
(PIP3). PIP3 serves as a docking site for the PH domain of
both Bruton’s tyrosine kinase, a Src-related tyrosine kinase
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that is involved in B cell antigen receptor-mediated activation
of PLCQ2 [20], and PLCQ itself.
The aim of our study was to investigate further the mech-
anism of PLC activation by Cvx, studying the e¡ects of two
structurally and functionally unrelated reagents on platelet
responses to this toxin, including Syk and PLCQ2 tyrosine
phosphorylation. The ¢rst inhibitor, phenylarsine oxide
(PAO), is a sulfhydryl reagent that inhibits PTPase. It is a
suitable inhibitor to be tested because PTPase inhibitors
have been shown to block collagen-induced platelet activation
[21,22], including PLCQ2 tyrosyl phosphorylation [22] ; PAO
also inhibits FcRI-induced myeloid oxidant burst signaling
in U937IF cells [23]. The second inhibitor, PI3-kinase inhib-
itor wortmannin, was used in an attempt to detect the
contributions of PI3-K activation to signaling triggered by
Cvx. Our ¢ndings suggest that both PTPase and PI3-K acti-
vation function as positive modulators of platelet activation
by Cvx.
2. Materials and methods
2.1. Materials
Cvx was puri¢ed from the venom of Crotalus durissus terri¢cus
from FUNED (Fundac°aìo Ezequiel Dias, Minas Gerais, Brazil) as
previously described [4]. Antiphosphotyrosine monoclonal antibody
(PY20), anti-PLCQ2 and anti-Syk polyclonal antibodies, and protein
A/G-Sepharose were from Santa Cruz Biotechnology (Santa Cruz,
CA). The peroxidase-coupled donkey anti-rabbit and sheep anti-
mouse IgGs, the chemiluminescent reagent ECL, [14C]5-hydroxytrypt-
amine and myo[2-3H]inositol were from Amersham (Les Ulis, France).
Dowex 1-X8 AG anion exchange resin (format form) was from Bio-
Rad (Richmond, CA). Collagen from equine tendons was from Horm
(Hormon-Chemie, Munich, Germany). Bovine serum albumin frac-
tion V (BSA), prostaglandin E1, apyrase fraction V, gelatin, phenyl-
arsine oxide, vanadate, fura 2-acetoxymethylester (fura 2-AM), and
Nonidet P40 were from Sigma (St. Louis, MO), and polyvinyl£uoride
membranes (PVDF) from Millipore (Bedford, MA). The PI3-kinase
inhibitors wortmannin and LY 294002 were from Calbiochem (San
Diego, CA).
2.2. Platelet preparation
Blood from healthy volunteers not on medication was collected on
acid-citrate-dextrose anticoagulant. Platelet-rich plasma was obtained
by centrifugation at 110Ug for 15 min. In some cases, platelets were
labeled by incubating PRP with 0.6 WM [14C]5-hydroxytryptamine for
30 min at 37‡C. After acidi¢cation of the PRP to pH 6.5 with 1/10 vol
of acid-citrate-dextrose anticoagulant and the addition of 100 nM
PGE1 and 25 Wg/ml apyrase, platelets were sedimented by centrifuga-
tion at 1100Ug for 15 min and washed twice by centrifugation in the
washing bu¡er (103 mM NaCl, 5 mM KCl, 1 mM MgCl2, 5 mM
glucose, 36 mM citric acid, pH 6.5, containing 3.5 mg/ml BSA, 100
nM PGE1, and 25 Wg/ml apyrase). Washed platelets were resuspended
at the concentrations indicated in the text in the reaction bu¡er con-
sisting of 5 mM HEPES, 137 mM NaCl, 2 mM KCl, 1 mM MgCl2, 12
mM NaHCO3, 0.3 mM NaH2PO4, 5.5 mM glucose, pH 7.4, contain-
ing 1.5 mg/ml BSA or 2.5 mg/ml gelatin.
2.3. Platelet aggregation and secretion
Washed platelets were preincubated with PAO or wortmannin for
2 and 10 min, respectively at 37‡C, before aggregation was initiated by
the addition of Cvx or collagen. Control experiments were performed
with platelets preincubated with a bu¡er containing the same concen-
tration of DMSO as that contained in the inhibitors. Experiments
were performed with stirring at 37‡C in a Chrono-Log aggregometer
(Chrono-Log Corp., Haverton, PA). Release of [14C]5-hydroxytrypt-
amine was measured as described previously [24]. Alternatively, plat-
elets were lysed for analysis of protein tyrosine phosphorylation or for
immunoprecipitation.
2.4. Measurement of intracellular Ca2 + concentration
Intracellular free calcium ([Ca2]i) transients were monitored by
fura-2 £uorescence as previously described. Brie£y, platelets loaded
with 2 WM fura 2-AM were washed twice and resuspended in a re-
action bu¡er. Platelets (2U108/ml) were then preincubated with 2 mM
CaCl2 or 2 mM EGTA in the cuvette prior to the addition of Cvx or
collagen. Fluorescence was measured at 37‡C using two excitation
wavelengths of 340 and 380 nm and an emission wavelength of 510
nm on an Hitachi H-2000 spectro£uorometer (Sciencetec, Les Ulis,
France). Ca2 concentrations were calculated using a Kd of 224 nM
for the interaction between fura 2 and Ca2 [24].
2.5. Measurement of inositol-phosphates production
After the ¢rst washing step, platelets (2U109/ml) were incubated at
37‡C for 3 h, with myo[2-3H]inositol (25 WCi/ml) in a reaction bu¡er
(without NaHCO3) at pH 7.4, in which 2 mM EDTA, 100 nM PGE1
and 25 Wg/ml apyrase were added to prevent platelet activation. After
washing, platelets were resuspended at 5U108/ml in a reaction bu¡er
containing 10 mM LiCl2. Platelets were incubated with 1 WM PAO,
0.1 WM wortmannin or DMSO as above. Platelets were activated by
2 nM Cvx or 2 Wg/ml collagen for 4 min in the aggregometer. Acti-
vation was stopped by ice-cold 0.1 M EDTA and centrifugation.
Platelets were lysed by 10 mM formic acid and two freezing and
thaw cycles and samples were neutralized with 10 mM ammoniac.
Total inositol phosphates were separated on a Dowex 1-X8 AG anion
exchange resin (format form). Following elution of [3H]inositol and
[3H]glycerophosphoinositol with 40 mM ammonium formate, total
inositol phosphates were eluted with 2 M ammonium formate. The
radioactivity present in all fractions as determined by scintillation
counting (Beckman Instruments).
2.6. Analysis of protein tyrosine phosphorylations
Platelets (200 Wl, 5U108/ml) were lysed by the addition of 20 Wl of a
10USDS lysis bu¡er composed of 0.625 M Tris pH 6.8, containing
50% (v/v) 2-mercaptoethanol, 30% SDS, 100 mM vanadate, and 10
mM PAO. Platelet lysates were heated for 5 min at 100‡C. Samples
were adjusted for their platelet content before analysis.
2.7. Immunoblotting studies
Proteins from whole platelet lysates or immunoprecipitated proteins
were separated by SDS-PAGE and transferred to PVDF membranes
in 50 mM Tris, 95 mM glycine, 20% methanol, containing 0.1% (w/v)
SDS and 100 WM Na2VO4. The membranes were blocked with 15 mg/
ml BSA in 20 mM Tris, 150 mM NaCl, pH 8 (TBS) and were in-
cubated with 1 Wg/ml PY20 in TBS containing 0.05% (v/v) Tween 20
and 0.1% BSA for 2 h at room temperature. Membranes were washed
in TBS-Tween and incubated with anti-mouse peroxidase-coupled sec-
ondary antibody diluted 1:7500. Following washing immunoblots
were developed using enhanced chemiluminescence detection. Equiv-
alent protein loading for immunoprecipitated proteins was veri¢ed by
reprobing with a relevant antibody.
2.8. Immunoprecipitation
Platelets (500 Wl, 5U108/ml) were lysed by the addition of 200 Wl of
3.5Uice-cold immunoprecipitation bu¡er (10 mM Tris, 300 mM
NaCl, 12 mM EDTA, pH 8, containing 1% Nonidet P40, 5 mM
Na2VO4, and 2 mM PMSF). After 30 min on ice, samples were
precleared by incubation with protein A-Sepharose for 15 min at
4‡C and centrifugation to limit non-speci¢c precipitation. Cleared
lysates adjusted for their platelet content were then incubated with
anti-PLCQ2, anti-Syk polyclonal antibody, or PY20 (1 Wg/ml) for 1 h
at 4‡C. After the addition of protein A/G-Sepharose, incubation was
continued overnight at 4‡C. Samples were centrifuged at 4500Ug for
2 min. The supernatant was kept for further precipitation, and the
protein A/G pellet was washed twice in the immunoprecipitation
bu¡er. Immunoprecipitated proteins were solubilized by 2% (w/v)
SDS reduced with 5% (v/v) 2-mercaptoethanol. In some experiments,
quanti¢cation of tyrosine phosphorylation of immunoprecipitated
proteins was performed in a Onescanner MacIntosh, and the analysis
was made with an NIH Image. Results are expressed as % of tyrosine
phosphorylation of at least two independent experiments; 100% was
settled as phosphorylation in the presence of inhibitor vehicle
(DMSO, 0.5^1%, v/v).
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3. Results and discussion
3.1. PAO inhibits Cvx- and collagen-induced platelet
aggregation, secretion, inositol phosphate production and
[Ca2+]i increase
Aggregation of washed platelets induced by an optimum
concentration of Cvx (2 nM) was inhibited by pretreatment
of platelets with PAO (Fig. 1A). The e¡ect of PAO is dose
dependent, with an IC50 of 0.4 WM. PAO also inhibited colla-
gen-induced platelet aggregation (Fig. 1A), while thrombin-
induced platelet aggregation was not signi¢cantly reduced by
PAO at concentrations up to 2.5 WM, in agreement with pre-
vious reports [21,22]. As platelet aggregation, dense-granule
release induced by Cvx or by collagen was inhibited by
PAO we have thus investigated the e¡ect of PAO on Cvx-
induced IPs production. Inhibition of Cvx- and collagen-in-
duced platelet aggregation by PAO was accompanied by more
than 65% and 45% inhibition of IP production, respectively
(Fig. 1B). Next, the e¡ects of PAO on the Cvx-induced in-
crease in Ca2 were studied. Convulxin induces Ca2 increase
in the presence and absence of external Ca2 (Fig. 1C) indi-
cating that Cvx induces intracellular Ca2 mobilization as well
as Ca2 entry, in agreement with previous results [6,8]. In the
presence of 0.1 WM PAO, Cvx-induced increase in [Ca2]i was
decreased by about 25%, while it was completely blocked by
1 WM PAO. These results indicate that an early step in the
signal transduction pathway induced by Cvx is susceptible to
PAO. Furthermore, at this point of our study, the observation
that PAO similarly inhibited platelet responses triggered by
Cvx or collagen favored the hypothesis that Cvx and collagen
induce platelet activation by a common pathway.
3.2. PAO does not inhibit Cvx-induced protein tyrosine
phosphorylation
The inhibition by PAO of Cvx-induced [Ca2]i increase in-
dicates that an early step of the signaling cascade triggered by
Cvx was blocked. Indeed, the observation that inositol-phos-
phates production was impaired by PAO, suggested that this
compound might inhibit PLC activation or activity. In fact,
PAO has previously been reported to inhibit tyrosine phos-
phorylation of PLCQ2 in collagen- and FcQRIIA-stimulated
platelets [22]. Since Cvx induces tyrosine phosphorylation of
several proteins including PLCQ2 and Syk, we have studied
the e¡ect of PAO on these responses. Non-stimulated platelets
contain constitutively tyrosine phosphorylated proteins, in
particular proteins of 55^60 kDa. Platelet pretreatment with
1 WM PAO alone slightly increased the intensity of some pro-
teins (Fig. 2A,B), probably by inhibiting constitutively acti-
vated PTPases. Fig. 2A shows that whole platelet protein
tyrosyl phosphorylation triggered by Cvx was increased by
pretreatment with PAO at concentrations that also attenuated
platelet aggregation, suggesting that the inhibitory e¡ect of
PAO is associated with inhibition of PTPases. In contrast,
the intensity of the protein tyrosine phosphorylation triggered
by collagen was not modi¢ed in the presence of 1 WM PAO
(Fig. 2B), con¢rming previous reports and providing evidence
to suggest that a di¡erent site from PTPase, yet to be identi-
¢ed, may be blocked by PAO in collagen-stimulated platelets
[22].
The e¡ects of PAO on the intensity and number of tyrosine-
phosphorylated proteins in Western blots of Cvx-stimulated
platelets may be explained by a change in the equilibrium
between the phosphorylation/dephosphorylation reactions to-
ward the phosphorylation reaction. Although our results do
not reveal the PAO inhibitory mechanism of Cvx-induced
platelet activation, they do support the contention that
PTPase activation has a positive modulatory function on plat-
elet activation [25^28]. Indeed, dephosphorylation of Src-like
kinases that are involved in signaling by Cvx and collagen
[13,14], results in the catalytic activation of Src-related kinases
[29]. More recently, it has also been shown that PAO blocks
FcQRI-induced myeloid oxidant signaling together with an
increase of the intensity and number of tyrosyl-phospho-
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Fig. 1. E¡ect of tyrosine phosphatase inhibitor, phenylarsine oxide
(PAO) on Cvx-induced platelet aggregation, secretion, inositol-phos-
phates production, and [Ca2]i increase. Comparison with collagen.
A: Washed platelets were incubated with bu¡er (a) or in the pres-
ence of 0.2 (b), 0.5 (c), or 1 WM PAO (d). Aggregation was initiated
(arrow) by 2 nM Cvx (left panel) or 1 Wg/ml collagen (right panel).
The percentage of serotonin released in indicated beside the curves.
B: E¡ect of PAO on Cvx- and collagen-induced inositol-phosphates
production. Washed platelets loaded with myo[233H]inositol were
stimulated by 2 nM Cvx (left panel) or 1 Wg/ml collagen (right pan-
el) in the absence of presence of PAO (1 WM). Separation of inositol
phosphates was performed as described in Section 2. Results are ex-
pressed as the increase in inositol phosphates over the basal level
(non-stimulated platelets) in the absence or presence of PAO. C: Ef-
fect of PAO on Cvx-induced calcium mobilization fura 2-loaded
platelets were preincubated with bu¡er (a), or PAO 0.1 WM (b) or
1 WM (c). Calcium increase was induced by 2 nM Cvx in the pres-
ence of 2 mM CaCl2 (left panel) or 2 mM EDTA (right panel).
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rylated proteins in U937IF cells [23]. It is of interest that this
event is accompanied by an augmentation of the interaction
of the adaptor protein Cbl with other phosphoproteins,
among them SHC and CRKL. Since Cvx also phosphorylates
Cbl in addition to syk, PLCQ2, the Fc receptor Q chain, and
the 36^38 kDa adaptor proteins [8^10], it is plausible to sug-
gest that some of these proteins bind to each other and that
this association should be modulated by the level of tyrosyl
phosphorylation and hence, by PTPases. In other words, ty-
rosine dephosphorylation is required for e¡ective transmission
of GPVI signaling to result in full platelet activation by Cvx
and at least in part, by collagen.
In an attempt to determine the site of inhibition of Cvx-
and collagen-induced platelet activation by PAO, we investi-
gated the e¡ects of this inhibitor on tyrosine phosphorylation
of Syk and PLCQ2 by immunoprecipitation assays (Fig.
3A,B). Although GPVI ligation by both collagen [22] and
Cvx induces a PAO-insensitive tyrosyl phosphorylation of
the tyrosine kinase Syk (Fig. 3B), PLCQ2 tyrosyl phosphoryl-
ation induced by collagen [22], but not by Cvx, is inhibited by
PAO (Fig. 3A). Di¡erences in signals triggered by Cvx and
collagen have been previously reported. In fact, we have
shown that inhibition of Cvx-, but not collagen-induced plat-
elet responses by PAO is accompanied by an increase in PTP.
In addition, PLCQ2 tyrosyl phosphorylation triggered by Cvx
occurs as early as 10 s after the Cvx addition to platelets [8,9],
whereas PLCQ2 is tyrosyl phosphorylated by collagen at later
time points [30,31]. Moreover, piceatannol, a Syk inhibitor,
blocks platelet aggregation and protein tyrosine phosphoryla-
tion triggered by collagen, whereas it produced only a partial
inhibition of Cvx-induced platelet aggregation [10]. Taking
into consideration that collagen may interact with several re-
ceptors at the platelet surface (GPIV, integrin K2L1, p65) [32^
35] while Cvx-induced platelet activation appears to occur
mainly through GPVI ligation [6,10], it is not surprising
that some di¡erences exist at the level of the signaling path-
ways and their regulation. In addition, our results indicate
that tyrosine phosphorylation of PLCQ2 and PLC activity
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Fig. 3. E¡ect of PAO on PLCQ2 and Syk phosphorylation triggered by Convulxin or collagen. A: PLCQ2 was immunoprecipitated from plate-
lets incubated with bu¡er (a, b, d) or PAO 1 WM (c, e) and activated by 2 nM Cvx (b, c) or 1 Wg/ml collagen (d, e). Blots were incubated with
anti-PY20 (i) and anti PLCQ2 (ii). B: Syk was immunoprecipitated from platelets incubated with bu¡er (a, b, d) or 1 WM PAO (c, e, f) before
activation with Cvx (b, c) or collagen (d^f). Blots were incubated with anti-PY20 (i) and anti-Syk (ii). The intensity of the phosphorylated
band (i) in d^f is proportional to the amount of protein (Syk) in the gel (ii). As a control, in f, the content of platelet protein loaded is 2.5
times higher than in d.
Fig. 2. E¡ect of PAO on platelet protein tyrosine phosphorylation induced by Convulxin or collagen. A: Washed platelets were incubated with
bu¡er (a, c) or PAO 1 WM (b, d) before activation by 2 nM Cvx for 20 s (lanes c, d). B: Washed platelets were incubated with bu¡er (a, c) or
PAO 1 WM (b, d) before activation by 1 Wg/ml collagen for 40 s (lanes c, d). In A and B platelets were lysed and proteins analyzed by immu-
noblotting with PY20. The same number of platelets (107) was present in all the wells.
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may uncouple, PLCQ2 being strongly phosphorylated in re-
sponse to Cvx in the presence of PAO but without producing
[Ca2]i increase and bringing inositol phosphates and platelet
aggregation to near basal levels. Uncoupling of tyrosine phos-
phorylation of PLCQ2 and production of inositol phosphates
has also been shown in platelets stimulated by Cvx, in the
presence of the cAMP increasing agent, forskolin [9]. Thus,
additional regulatory mechanisms may be involved in the ex-
pression of PLC activity by Cvx-induced tyrosine-phosphoryl-
ated PLCQ2.
3.3. PI3-kinase is involved in Cvx- and collagen-induced
platelet activation
It has been shown that the binding of growth factors to
appropriate cells is accompanied by tyrosyl phosphorylation
of the receptor with its subsequent interaction with PLCQ1,
leading to its tyrosyl phosphorylation; however, PLCQ1 ex-
press PLC activity once a lipid kinase, PI3-kinase, is also
activated by a receptor-mediated mechanism [18,19,36^39].
Indeed, PI3-K is essential for PLCQ activity because the phos-
phorylation of the 3P position of the inositol ring of
PtdIns(4,5)P2 produces PtdIns(3,4,5)P3, a phospholipid that
serves as a docking site for the pleckstrin homology (PH)
domain of tyrosyl-phosphorylated PLCQ, targeting the enzyme
to the vicinity of its membrane substrate, PtdIns(4,5)P2
[18,19]. To determine whether PI3-kinase was involved in
Cvx-induced platelet activation, experiments were performed
in the presence of the PI3-kinase-speci¢c inhibitor, wortman-
nin. Cvx-, as well as collagen-induced platelet aggregation and
secretion, was largely inhibited by wortmannin, suggesting
that an early step of platelet activation was blocked (Fig.
4A). Another PI3-K inhibitor, LY294002, inhibited Cvx-in-
duced platelet aggregation and secretion as e⁄ciently as wort-
mannin but was less potent in inhibiting collagen-induced
platelet aggregation and secretion (not shown). Wortmannin
at concentrations that brought platelet aggregation to basal
levels also caused 80% inhibition of IP production triggered
by Cvx (Fig. 4B) and 50% triggered by collagen (Fig. 4B). The
¢nding that total inhibition of platelet aggregation by wort-
mannin was accompanied by partial inhibition of IP produc-
tion by Cvx and collagen suggest that (i) wortmannin (and
PAO) may also a¡ect the platelet aggregation itself (e.g. mod-
ulation of integrin KIIbL3 function) and/or (ii) additional
mechanism, PI3-kinase-independent, may trigger IP produc-
tion in Cvx- and collagen-stimulated platelets such as PLA2-
dependent, TXA2-mediated IP production, or via tyrosine-
kinase activation (see below). Fig. 4C shows that wortmannin
lowered the Cvx-induced increase in [Ca2]i in the presence
and in the absence of external Ca2 (Fig. 4C). The e¡ects of
PI3-kinase inhibition on PLCQ2 phosphorylation were thus
tested (Fig. 4D). At concentrations that completely blocked
platelet aggregation, wortmannin caused 55% and 48% inhi-
bition of tyrosine phosphorylation of PLCQ2 when the agonist
was Cvx or collagen, respectively.
Taken together, our results suggest that inhibition by wort-
mannin of Cvx and collagen-induced PLCQ2 activation may
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Fig. 4. E¡ect of PI3-kinase inhibition on Cvx-induced platelet aggregation, secretion, inositol-phosphates production, [Ca2]i increase, and
PLCQ2 phosphorylation. Comparison with collagen. A: Washed platelets were incubated with DMSO (a) or 100 nM wortmannin (b) before ac-
tivation with 2 nM Cvx (left) or 1 Wg/ml collagen (right). The percentage of serotonin released is indicated beside the curves. B: Platelets
loaded with myo[233H]inositol were stimulated by 2 nM Cvx (left panel) or collagen (right panel) in the absence or presence of wortmannin
(0.1 WM). Separation of inositol phosphates was perfomed as described in Section 2. Results are expressed as the increase in inositol phosphates
over the basal level (non-stimulated platelets) in the absence or presence of wortmannin. C: Fura-2-loaded platelets were incubated with bu¡er
(a, c) or 100 nM wortmannin (b, d) before activation with 200 pM Cvx in the presence of 2 mM CaCl2 (a, b) or 2 mM EDTA (c, d). D: Ty-
rosine phosphorylation of PLCQ2 was carried out as in Fig. 3. (a) non-activated platelets; (b) Cvx 75 pM for 20 s; (c) wortmannin 100 nM for
5 min followed by Cvx as in b; (d) collagen, 1 Wg/ml for 40 s; (e) wortmannin 100 nM followed by collagen as in d. Blots were incubated with
anti-PY20 (i) and anti-PLCQ2 (ii).
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proceed by at least two mechanisms. First, the inhibition of
PI(3,4,5)P3 production may impair PLCQ2 docking at the
membrane in the proximity of its substrate PI(4,5)P2 [18,19].
Indeed, a number of papers have shown that the biological
e¡ects mediated by PI3-K activation occur independently of
tyrosine phosphorylation; (i) activation of phospholipase C-Q
by PI(3,4,5)P3 occurs independently of tyrosine phosphoryla-
tion [40^42], (ii) PI(3,4,5,)P3 triggers Ca2 in£ux in rabbit
platelets, leading to platelet aggregation [43], (iii) wortmannin
treatment did not in£uence the ability of PDGF to induce
tyrosine phosphorylation of PLCQ1 in COS-1 cells but largely
decreased Ins(1,4,5)P3 production [19], (iv) FcQRIIA medi-
ated-platelet secretion and aggregation, as well as phospholi-
pase C (PLC) activation, but not PLCQ2 tyrosyl phosphoryl-
ation, is abolished by wortmannin or LY294002 [40].
Second, since we observed partial but reproducible inhibi-
tion of PLCQ2 tyrosyl phosphorylation by wortmannin in
Cvx- and collagen-stimulated platelets, PI3-K may be also
involved in an alternative pathway leading to PLCQ2 tyrosyl
phosphorylation other than, or complementary to, Fc recep-
tor Q chain-Syk-mediated tyrosyl phosphorylation. This path-
way may be the activation of Bruton’s tyrosine kinase, a PH
domain containing Src-related PTK related to PLCQ2 activa-
tion in the B cell [20] and in collagen-activated platelets [44].
Additional tyrosine kinases and adaptor molecules may also
be involved in this event. Finally, the ¢nding that the p85
subunit of PI3-K associates with the Fc receptor Q chain in
platelets stimulated with collagen and Cvx, provides an addi-
tional support to the contention that PI-3K participates in the
GPVI-Fc receptor Q chain collagen receptor [45].
In conclusion, our results show that the unrelated inhibitors
PAO and wortmannin similarly a¡ect platelet function in
Cvx-stimulated platelets by a mechanism that uncouples tyro-
syl phosphorylation of PLCQ2 and PLC activity. Our results
provide evidence that phosphoinositide metabolism in Cvx-
stimulated platelets is a highly regulated and redundant event
that may involve cross-talk between tyrosine kinases, lipid
kinases, adaptor proteins, tyrosine and lipid phosphatase.
The molecular mechanism involved in this cascade of signal-
ing events awaits further investigation.
Acknowledgements: This work was supported in part by grants from
the European Community (CI1*CT940073) and University Paris 7.
The authors acknowledge Brenda Rae Marshall for the preparation
of the manuscript.
References
[1] Prado-Franceschi, J. and Vital-Brazil, O. (1981) Toxicon 19, 875^
887.
[2] Marlas, G. (1985) Biochimie 67, 1231^1239.
[3] Leduc, M. and Bon, C. (1998) Biochem. J. 333, 389^393.
[4] Francischetti, I.M.B., Saliou, B., Leduc, M., Carlini, C.R., Hat-
mi, M., Randon, J., Faili, A. and Bon, C. (1997) Toxicon 35,
1217^1228.
[5] Vargaftig, B.B., Prado-Franceschi, J., Chignard, M., Lefort, J.
and Marlas, G. (1980) Eur. J. Pharmacol. 68, 451^464.
[6] Jandrot-Perrus, M., Lagrue, A.-H., Okuma, M. and Bon, C.
(1997) J. Biol. Chem. 272, 27035^27041.
[7] Faili, A., Randon, J., Francischetti, I.M.B., Vargaftig, B.B. and
Hatmi, M. (1994) Biochem. J. 298, 87^91.
[8] Francischetti, I.M.B., Ghazaleh, F.A., Reis, R.A.M., Carlini,
C.R. and Guimaraìes, J.A. (1998) Arch. Biochem. Biophys. 353,
239^250.
[9] Francischetti, I.M.B., Carlini, C.R. and Guimaraìes, J.A. (1998)
Arch. Biochem. Biophys. 354, 255^262.
[10] PolgaŁr, J., Clemetson, J.M., Kehrel, B., Wiedemann, M., Mag-
negnat, E.M., Wells, T.N.C. and Clemetson, K.J. (1997) J. Biol.
Chem. 272, 13576^13583.
[11] Gibbins, J.M., Okuma, M., Farndale, R., Barnes, M. and Wat-
son, S.P. (1997) FEBS Lett. 413, 255^259.
[12] Tsuji, M., Ezumi, Y., Arai, M. and Takayama, H. (1997) J. Biol.
Chem. 38, 23528^23531.
[13] Ezumi, Y., Shindoh, K., Tsuji, M. and Takayama, H. (1998)
J. Exp. Med. 188, 267^276.
[14] Watson, S.P. and Gibbins, J. (1998) Immunol. Today 19, 260^
264.
[15] Poole, A., Gibbins, J.M., Turner, M., van Vugt, M.J., van de
Winkel, J.G., Saito, T., Tybulewicz, V.L. and Watson, S.P.
(1997) EMBO J. 16, 2333^2341.
[16] Yanaga, F., Poole, A., Asselin, J., Blake, R., Schieven, G.L.,
Clark, E.A., Law, C.H. and Watson, S.P. (1995) Biochem.
J. 311, 471^478.
[17] Neel, G. (1997) Curr. Opin. Immunol. 9, 405^420.
[18] Rhee, S.G. and Bao, Y.S. (1997) J. Biol. Chem. 272, 15045^
15048.
[19] Falasca, M., Logan, S.K., Lehto, V.P., Baccante, G., Lemmon,
M.A. and Schlessinger, J. (1998) EMBO J. 17, 414^422.
[20] Takata, M. and Kurrosaki, T. (1996) J. Exp. Med. 184, 31^40.
[21] Greenwalt, D.A. and Tandon, N.N. (1994) Br. J. Haematol. 88,
830^838.
[22] Yanaga, F., Asselin, J., Schieven, G.L. and Watson, S.P. (1995)
FEBS Lett. 368, 377^380.
[23] Erdreich-Epstein, A., Liu, M., Liu, Y. and Durden, D.L. (1997)
Exp. Cell Res. 237, 288^295.
[24] Grynkiewicz, G., Poenie, M. and Tsien, R.Y. (1985) J. Biol.
Chem. 260, 3440^3450.
[25] Levy-Toledano, S., Gallet, C., Nadal, F., Bryckaert, M., Ma-
clouf, J. and Rosa, J.P. (1997) Thromb. Haemost. 78, 226^
233.
[26] Frangeoni, J.V., Oda, A., Smith, M., Salzman, E.W. and Neel,
B.G. (1993) EMBO J. 12, 4843^4856.
[27] Ezumi, Y., Takayama, H. and Okuma, M. (1995) J. Biol. Chem.
20, 11927^11934.
[28] Giuriato, S., Payrastre, B., Drayer, A.L., Plantavid, M., Wo-
scholski, R., Parker, P., Erneux, C. and Chap, H. (1997) J. Biol.
Chem. 272, 26857^26863.
[29] Corey, S.J. and Anderson, S.M. (1999) Blood 93, 1^14.
[30] Daniel, J.L., Dangelmaier, C. and Smith, J.B. (1994) Biochem. J.
302, 617^622.
[31] Blake, R.A., Schieven, G.L. and Watson, S.P. (1994) FEBS Lett.
353, 212^216.
[32] Tandon, N.N., Kralisz, U. and Jamieson, G.A. (1989) J. Biol.
Chem. 264, 7576^7583.
[33] Santoro, S. and Zutter, M.M. (1995) Thromb. Haemost. 74, 813^
821.
[34] Chiang, T.M., Rinaldy, A. and Kang, A.H. (1997) J. Clin. Invest.
100, 514^521.
[35] Ichinohe, T., Takayama, T., Ezumi, Y., Yanagi, S., Yamamura,
H. and Okuma, M. (1995) J. Biol. Chem. 270, 28029^28036.
[36] Li, Z., Wahl, M., Eguinoa, A., Stephens, L.R., Hawkins, P.T.
and Witte, O.N. (1997) Proc. Natl. Acad. Sci. USA 94, 13820^
13825.
[37] Rittenhouse, S.E. (1996) Blood 88, 4401^4414.
[38] Klarlund, J.K., Guilherme, A., Holik, J.J., Virbasius, J.V., Chaw-
la, A. and Czech, M.P. (1998) Science 275, 1927^1930.
[39] Guilherme, A., Klarlund, J.K., Krystal, G. and Czech, M.P.
(1996) J. Biol. Chem. 271, 29533^29536.
[40] Gratacap, M.-P., Payrastre, B., Viala, C., Mauco, G., Plantavid,
M. and Chap, H. (1998) J. Biol. Chem. 273, 24314^24321.
[41] Bae, Y.S., Cantley, L.G., Chen, C.S., Kim, S.R., Kwon, K.S. and
Rhee, S.G. (1998) J. Biol. Chem. 273, 4465^4469.
[42] Rameh, L.E., Rhee, S.G., Spokes, K., Kazlauskas, A., Cantley,
L.C. and Cantley, L.G. (1998) J. Biol. Chem. 273, 23750^23757.
[43] Lu, P., Wang, D. and Chen, C. (1998) Biochemistry 37, 9776^
9783.
[44] Quek, L.S., Bolen, J. and Watson, S.P. (1998) Curr. Biol. 8,
1137^1140.
[45] Gibbins, J.M., Briddon, S., Shutes, A., Vugt, M.J., Winkel,
J.G.J., Saito, T. and Watson, S.P. (1998) J. Biol. Chem. 273,
34437^34443.
FEBS 21808 29-3-99
A. Lagrue et al./FEBS Letters 448 (1999) 95^100100
